What is INVO Fertility, Inc's earnings per share (EPS)?

INVO Fertility, Inc (IVF) reported diluted earnings per share of $-214.64 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

INVO Fertility, Inc Financials

IVF

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows INVO Fertility, Inc (IVF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IVF FY2024 2026-06-02

Revenue recovery is easing cash burn, but overhead-heavy operations and near-term liabilities still shape the business.

From FY2023 to FY2024, net loss widened to -$9.1M even as operating cash burn improved to -$3.0M. That matters because reported losses and cash consumption are now diverging: the income statement is reflecting more non-cash charges, with depreciation and amortization rising to $920K, while the business is using less cash to support each dollar of activity than it did a year earlier.

The operating model is still overhead led: FY2024 SG&A was $9.1M against gross profit of just $2.8M. That helps explain why better gross economics, including a gross margin of 43.1%, have not yet turned into a narrower operating loss: scale is improving the sale itself, but the cost base still looks built for a much larger revenue level.

Liquidity strain remains the clearest balance-sheet signal, with cash at only $620K against current liabilities of $17.9M. The current ratio fell to 0.07x, yet long-term debt was just $1.1M, which suggests the financing tension sits in short-term obligations more than in traditional debt leverage.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of INVO Fertility, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

INVO Fertility, Inc has an operating margin of -105.8%, meaning the company retains $-106 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -101.5% the prior year.

Growth

100

INVO Fertility, Inc's revenue grew a modest 4.7% year-over-year to $6.8M. This slow but positive growth earns a score of 100/100.

Leverage

100

INVO Fertility, Inc carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

INVO Fertility, Inc's current ratio of 0.27 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

While INVO Fertility, Inc generated -$7.0M in operating cash flow, capex of $43K consumed most of it, leaving -$7.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

INVO Fertility, Inc generates a -322.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -73.6% the prior year.

Piotroski F-Score Weak

3/9

INVO Fertility, Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.30x

For every $1 of reported earnings, INVO Fertility, Inc generates $0.30 in operating cash flow (-$7.0M OCF vs -$23.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-5.6x

INVO Fertility, Inc earns $-5.6 in operating income for every $1 of interest expense (-$7.2M vs $1.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.8M

YoY+4.7%

5Y CAGR+45.8%

10Y CAGR+89.1%

INVO Fertility, Inc generated $6.8M in revenue in fiscal year 2025. This represents an increase of 4.7% from the prior year.

EBITDA

-$6.6M

YoY-14.9%

INVO Fertility, Inc's EBITDA was -$6.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.9% from the prior year.

Net Income

-$23.3M

YoY-151.9%

INVO Fertility, Inc reported -$23.3M in net income in fiscal year 2025. This represents a decrease of 151.9% from the prior year.

EPS (Diluted)

$-214.64

INVO Fertility, Inc earned $-214.64 per diluted share (EPS) in fiscal year 2025. This represents an increase of 94.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$7.1M

YoY-123.5%

INVO Fertility, Inc generated -$7.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 123.5% from the prior year.

Cash & Debt

$2.1M

YoY+235.4%

5Y CAGR-27.1%

10Y CAGR+15.5%

INVO Fertility, Inc held $2.1M in cash against $745K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

15M

INVO Fertility, Inc had 15M shares outstanding in fiscal year 2025. This represents an increase of 206.5% from the prior year.

Margins & Returns

Gross Margin

99.6%

YoY-0.3pp

5Y CAGR+8.1pp

10Y CAGR+66.4pp

INVO Fertility, Inc's gross margin was 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.

Operating Margin

-105.8%

YoY-4.3pp

5Y CAGR+425.9pp

10Y CAGR+4985.1pp

INVO Fertility, Inc's operating margin was -105.8% in fiscal year 2025, reflecting core business profitability. This is down 4.3 percentage points from the prior year.

Net Margin

-340.9%

YoY-199.2pp

5Y CAGR+463.8pp

INVO Fertility, Inc's net profit margin was -340.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 199.2 percentage points from the prior year.

Return on Equity

-322.8%

YoY-249.3pp

5Y CAGR-177.5pp

INVO Fertility, Inc's ROE was -322.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 249.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$5K

YoY+0.0%

5Y CAGR-58.5%

INVO Fertility, Inc invested $5K in research and development in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$43K

YoY-76.4%

5Y CAGR-2.5%

INVO Fertility, Inc invested $43K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 76.4% from the prior year.

IVF Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$6.8M+4.7%	$6.5M+116.3%	$3.0M+267.4%	$822K-80.2%	$4.2M+301.1%	$1.0M
Cost of Revenue	$31K+150.6%	$12K-99.4%	$2.0M+587.6%	$287K+127.1%	$126K+59.8%	$79K
Gross Profit	$6.8M+4.5%	$6.5M+522.3%	$1.0M+113.5%	$491K-87.8%	$4.0M+323.3%	$949K
R&D Expenses	$5K0.0%	$5K-97.1%	$166K-69.5%	$544K+151.4%	$216K-45.7%	$398K
SG&A Expenses	$7.7M-4.6%	$8.1M+7.7%	$7.5M-25.0%	$10.0M+10.7%	$9.0M+48.6%	$6.1M
Operating Income	-$7.2M-9.2%	-$6.6M+2.1%	-$6.8M+36.3%	-$10.6M-103.7%	-$5.2M+5.4%	-$5.5M
Interest Expense	$1.3M+23.3%	$1.1M+14.1%	$926K+1457.6%	$59K-95.3%	$1.3M-55.4%	$2.8M
Income Tax	-$150K-207.3%	$140K+404.6%	$28K+867.5%	$3K-39.7%	$5K+13133.3%	$36
Net Income	-$23.3M-151.9%	-$9.3M-15.2%	-$8.0M+26.2%	-$10.9M-63.7%	-$6.7M+20.3%	-$8.3M
EPS (Diluted)	$-214.64	$-3782.65	$-67.37-274.9%	$-17.97-2752.4%	$-0.63+58.6%	$-1.52

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.6M-9.9%	$1.8M-5.7%	$1.9M+13.8%	$1.6M-2.9%	$1.7M+17.6%	$1.4M-22.0%	$1.8M+16.5%	$1.6M
Cost of Revenue	N/A	N/A	N/A	$1.1M+139.4%	-$2.7M-373.2%	$988K+14.7%	$862K-0.1%	$862K
Gross Profit	N/A	N/A	N/A	$573K-86.9%	$4.4M+886.3%	$445K-54.4%	$975K+36.5%	$714K
R&D Expenses	N/A	N/A	N/A	$266K	N/A	N/A	N/A	$5K
SG&A Expenses	$816K-61.7%	$2.1M-3.0%	$2.2M-14.1%	$2.6M+3.7%	$2.5M+62.6%	$1.5M-42.8%	$2.6M+83.8%	$1.4M
Operating Income	$14.5M+986.3%	-$1.6M+45.3%	-$3.0M+82.5%	-$17.1M-770.0%	-$2.0M-51.2%	-$1.3M+29.8%	-$1.9M-22.9%	-$1.5M
Interest Expense	$1.2M+754.7%	$146K-34.1%	$221K+171.1%	-$311K-152.4%	$594K+117.2%	$274K-26.0%	$370K+303.9%	-$181K
Income Tax	N/A	N/A	N/A	N/A	N/A	$29K	N/A	$2K
Net Income	$1.1M+132.3%	-$3.4M+6.2%	-$3.6M+79.2%	-$17.4M-359.6%	-$3.8M-132.2%	-$1.6M+27.4%	-$2.2M-40.6%	-$1.6M
EPS (Diluted)	N/A	$-39.40+89.2%	$-364.23-2806.9%	$-12.53	N/A	$-15.11+32.5%	$-22.39-196.6%	$-7.55

IVF Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$20.2M-56.1%	$46.1M+149.0%	$18.5M+398.8%	$3.7M-62.9%	$10.0M-8.7%	$10.9M
Current Assets	$2.8M+119.8%	$1.3M-0.3%	$1.3M+102.8%	$621K-90.2%	$6.3M-40.2%	$10.5M
Cash & Equivalents	$2.1M+235.4%	$620K+166.5%	$232K+157.9%	$90K-98.4%	$5.7M-43.7%	$10.1M
Inventory	$225K+2.5%	$220K-16.9%	$265K+0.3%	$264K-8.4%	$288K+8.4%	$265K
Accounts Receivable	$217K+92.1%	$113K-19.5%	$141K+82.2%	$77K+52.9%	$50K+132.6%	$22K
Goodwill	$5.9M0.0%	$5.9M0.0%	$5.9M	N/A	N/A	N/A
Total Liabilities	$13.0M-50.1%	$26.0M+47.8%	$17.6M+275.8%	$4.7M+74.7%	$2.7M-48.4%	$5.2M
Current Liabilities	$10.3M-42.2%	$17.9M+123.3%	$8.0M+139.8%	$3.3M+184.2%	$1.2M-48.7%	$2.3M
Long-Term Debt	$745K-34.0%	$1.1M	N/A	N/A	N/A	N/A
Total Equity	$7.2M-42.6%	$12.6M+1309.5%	$893K+191.3%	-$978K-113.4%	$7.3M+27.3%	$5.7M
Retained Earnings	-$91.4M-35.7%	-$67.3M-16.4%	-$57.8M-16.1%	-$49.8M-28.0%	-$38.9M-20.6%	-$32.2M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$20.2M+7.4%	$18.8M-2.5%	$19.3M-39.1%	$31.7M-31.1%	$46.1M+170.7%	$17.0M-4.1%	$17.8M+2.4%	$17.3M
Current Assets	$2.8M+142.9%	$1.1M-18.8%	$1.4M-10.8%	$1.6M+24.9%	$1.3M-35.8%	$2.0M-18.3%	$2.4M+38.9%	$1.7M
Cash & Equivalents	$2.1M+483.8%	$356K-35.2%	$549K-34.7%	$840K+35.7%	$620K+23.9%	$500K-44.4%	$900K+89.4%	$475K
Inventory	$225K+17.5%	$192K-9.8%	$213K-1.8%	$216K-1.5%	$220K-9.0%	$242K-3.4%	$250K-6.2%	$266K
Accounts Receivable	$217K-20.8%	$274K+13.2%	$242K+39.5%	$174K+53.5%	$113K-56.0%	$257K-0.1%	$257K+45.4%	$177K
Goodwill	$5.9M0.0%	$5.9M0.0%	$5.9M-33.9%	$8.9M+51.2%	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$5.9M
Total Liabilities	$13.0M-0.1%	$13.0M-50.5%	$26.3M-55.2%	$58.8M+125.8%	$26.0M+52.8%	$17.0M+4.0%	$16.4M-5.4%	$17.3M
Current Liabilities	$10.3M+13.2%	$9.1M-24.8%	$12.1M-35.2%	$18.7M+4.8%	$17.9M+106.4%	$8.7M+8.8%	$8.0M-9.6%	$8.8M
Long-Term Debt	$745K-21.7%	$952K-8.6%	$1.0M	N/A	$1.1M	N/A	N/A	N/A
Total Equity	$7.2M+24.2%	$5.8M+183.2%	-$7.0M+74.1%	-$27.0M-314.9%	$12.6M+54073.1%	-$23K-101.7%	$1.4M+13327.0%	$10K
Retained Earnings	-$91.4M+0.9%	-$92.2M-4.1%	-$88.5M-4.3%	-$84.9M-26.1%	-$67.3M-6.0%	-$63.5M-2.6%	-$61.9M-4.2%	-$59.4M

IVF Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$7.0M-135.8%	-$3.0M+37.4%	-$4.8M+28.0%	-$6.6M-9.5%	-$6.0M-26.3%	-$4.8M
Capital Expenditures	$43K-76.4%	$184K-58.7%	$445K+4023.5%	$11K-97.4%	$416K+743.9%	$49K
Free Cash Flow	-$7.1M-123.5%	-$3.2M+39.3%	-$5.2M+21.4%	-$6.6M-2.6%	-$6.4M-33.6%	-$4.8M
Investing Cash Flow	-$2.7M-854.5%	$364K+114.6%	-$2.5M-2971.9%	-$81K+96.2%	-$2.2M-1050.0%	-$187K
Financing Cash Flow	$11.1M+255.7%	$3.1M-57.8%	$7.4M+578.3%	$1.1M-71.1%	$3.8M-72.7%	$13.8M
Dividends Paid	$719K	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$25K+101.4%	-$1.8M-3.4%	-$1.7M+51.6%	-$3.5M-474.3%	-$617K+3.7%	-$641K+56.0%	-$1.5M-458.7%	-$261K
Capital Expenditures	$12K+46.7%	$8K-9.2%	$9K-39.4%	$15K-81.4%	$79K	$0-100.0%	$55K+10.9%	$50K
Free Cash Flow	$13K+100.7%	-$1.8M-3.4%	-$1.7M+51.5%	-$3.6M-411.3%	-$696K-8.7%	-$641K+57.6%	-$1.5M-387.0%	-$310K
Investing Cash Flow	-$2.7M-33481.3%	-$8K+47.8%	-$15K-5.4%	-$15K-103.7%	$393K	$0+100.0%	-$5K+78.7%	-$24K
Financing Cash Flow	$4.4M+176.8%	$1.6M+10.4%	$1.4M-60.6%	$3.7M+640.7%	$494K+191.5%	$169K-91.2%	$1.9M+265.7%	$527K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IVF Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	99.6%-0.3pp	99.8%+65.1pp	34.7%-25.0pp	59.7%-36.8pp	96.5%+5.1pp	91.4%
Operating Margin	-105.8%-4.3pp	-101.5%+122.6pp	-224.0%+1068.4pp	-1292.5%-1167.1pp	-125.4%+406.3pp	-531.7%
Net Margin	-340.9%-199.2pp	-141.8%+124.3pp	-266.0%+1058.8pp	-1324.8%-1164.8pp	-160.0%+644.8pp	-804.7%
Return on Equity	-322.8%-249.3pp	-73.6%+826.3pp	-899.9%	N/A	-91.0%+54.3pp	-145.3%
Return on Assets	-115.3%-95.3pp	-20.1%+23.3pp	-43.4%+250.2pp	-293.6%-227.0pp	-66.6%+9.7pp	-76.3%
Current Ratio	0.27+0.2	0.07-0.1	0.16-0.0	0.19-5.2	5.37+0.8	4.61
Debt-to-Equity	0.10+0.0	0.09-19.6	19.73+24.5	-4.79-5.2	0.37-0.5	0.91
FCF Margin	-103.2%-54.8pp	-48.4%+123.8pp	-172.2%+632.3pp	-804.4%-649.5pp	-154.9%+310.2pp	-465.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	35.0%-225.1pp	260.1%+229.1pp	31.0%-22.1pp	53.1%+7.8pp	45.3%
Operating Margin	915.5%+1008.6pp	-93.1%+67.4pp	-160.4%+884.5pp	-1044.9%-928.3pp	-116.6%-25.9pp	-90.7%+10.1pp	-100.9%-5.2pp	-95.7%
Net Margin	69.2%+262.4pp	-193.3%+0.9pp	-194.2%+868.8pp	-1063.0%-838.4pp	-224.6%-110.8pp	-113.8%+8.5pp	-122.2%-21.0pp	-101.3%
Return on Equity	15.2%+73.5pp	-58.4%+142.5pp	-200.8%+321.0pp	-521.8%-491.7pp	-30.1%	N/A	-164.7%+15556.8pp	-15721.4%
Return on Assets	5.4%+23.4pp	-18.0%+0.7pp	-18.7%+36.1pp	-54.8%-46.6pp	-8.2%+1.4pp	-9.6%+3.1pp	-12.7%-3.4pp	-9.2%
Current Ratio	0.27+0.1	0.120.0	0.12+0.0	0.08+0.0	0.07-0.2	0.23-0.1	0.30+0.1	0.20
Debt-to-Equity	0.10-0.1	0.16+0.3	-0.15+2.0	-2.17-2.3	0.09+731.0	-730.95-743.0	12.02-1694.6	1706.60
FCF Margin	0.9%+102.4pp	-101.6%-8.9pp	-92.6%+124.8pp	-217.5%-176.2pp	-41.3%+3.4pp	-44.7%+37.5pp	-82.3%-62.6pp	-19.7%

Note: The current ratio is below 1.0 (0.27), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Venus Concept Inc VERO

$2.1M

Tivic Health Systems Inc TIVC

$4.0M

Nanovibronix Inc NAOV

$4.4M

Ra Medical Systems, Inc. RMED

$3.8M

Nuwellis Inc NUWE

$1.3M

Frequently Asked Questions

What is INVO Fertility, Inc's annual revenue?

INVO Fertility, Inc (IVF) reported $6.8M in total revenue for fiscal year 2025. This represents a 4.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is INVO Fertility, Inc's revenue growing?

INVO Fertility, Inc (IVF) revenue grew by 4.7% year-over-year, from $6.5M to $6.8M in fiscal year 2025.

Is INVO Fertility, Inc profitable?

No, INVO Fertility, Inc (IVF) reported a net income of -$23.3M in fiscal year 2025, with a net profit margin of -340.9%.

What is INVO Fertility, Inc's EBITDA?

INVO Fertility, Inc (IVF) had EBITDA of -$6.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does INVO Fertility, Inc have?

As of fiscal year 2025, INVO Fertility, Inc (IVF) had $2.1M in cash and equivalents against $745K in long-term debt.

What is INVO Fertility, Inc's gross margin?

INVO Fertility, Inc (IVF) had a gross margin of 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is INVO Fertility, Inc's operating margin?

INVO Fertility, Inc (IVF) had an operating margin of -105.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is INVO Fertility, Inc's net profit margin?

INVO Fertility, Inc (IVF) had a net profit margin of -340.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is INVO Fertility, Inc's return on equity (ROE)?

INVO Fertility, Inc (IVF) has a return on equity of -322.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is INVO Fertility, Inc's free cash flow?

INVO Fertility, Inc (IVF) generated -$7.1M in free cash flow during fiscal year 2025. This represents a -123.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is INVO Fertility, Inc's operating cash flow?

INVO Fertility, Inc (IVF) generated -$7.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are INVO Fertility, Inc's total assets?

INVO Fertility, Inc (IVF) had $20.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are INVO Fertility, Inc's capital expenditures?

INVO Fertility, Inc (IVF) invested $43K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does INVO Fertility, Inc spend on research and development?

INVO Fertility, Inc (IVF) invested $5K in research and development during fiscal year 2025.

How many shares does INVO Fertility, Inc have outstanding?

INVO Fertility, Inc (IVF) had 15M shares outstanding as of fiscal year 2025.

What is INVO Fertility, Inc's current ratio?

INVO Fertility, Inc (IVF) had a current ratio of 0.27 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is INVO Fertility, Inc's debt-to-equity ratio?

INVO Fertility, Inc (IVF) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is INVO Fertility, Inc's return on assets (ROA)?

INVO Fertility, Inc (IVF) had a return on assets of -115.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is INVO Fertility, Inc's cash runway?

Based on fiscal year 2025 data, INVO Fertility, Inc (IVF) had $2.1M in cash against an annual operating cash burn of $7.0M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is INVO Fertility, Inc's Piotroski F-Score?

INVO Fertility, Inc (IVF) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are INVO Fertility, Inc's earnings high quality?

INVO Fertility, Inc (IVF) has an earnings quality ratio of 0.30x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can INVO Fertility, Inc cover its interest payments?

INVO Fertility, Inc (IVF) has an interest coverage ratio of -5.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is INVO Fertility, Inc?

INVO Fertility, Inc (IVF) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.